Literature DB >> 20136916

Correlation between BMI and PASI in patients affected by moderate to severe psoriasis undergoing biological therapy.

F Bardazzi1, R Balestri, E Baldi, A Antonucci, S De Tommaso, A Patrizi.   

Abstract

Obesity is common in psoriatic patients, and it has been shown to be important for many aspects of the condition. In particular, low-calorie diets can improve the symptoms and response to treatment in pustular psoriasis. The present study investigates the influence of body-weight alteration on the disease's clinical manifestations in moderate to severe psoriasis patients treated with biological drugs. Finally, the influence of a caloric restriction was assessed. This observational transversal study enrolled 33 patients attending our Severe Psoriasis Outpatient Clinic, who were treated with biological drugs. Body Mass Index (BMI) was used as a diagnostic indicator of being overweight and of obesity. Waist circumference was also measured. Body weight and Psoriasis Area Severity Index (PASI) index were measured at follow-up visits at 4 and 8 months. Nonparametric test of Mann-Whitney was used to detect the differences between patient groups. Fisher's exact test was performed to evaluate the different results depending on the therapeutic changes of BMI. There was a strong prevalence of overweight-obese individuals in the group with a mean BMI of 30.59 +/- 6.94. Waist circumference was also above normal in the majority of the patients. Obese patients had a PASI index higher than the average of the whole group (25.03 +/- 12.43), with grade III obese patients having an average PASI of 44 +/- 3.37. At the first and second follow-ups, patients who put on weight did not achieve PASI 50; patients who had a stable weight presented variable response to treatment, while patients who decreased their weight achieved PASI 90 or PASI 75 even when not responding at the first. Further studies are needed to understand if the poor response observed in heavier patients is due to biological drugs pharmacokinetics or because therapy should be BMI based rather than administered in fixed doses, posing then an ethical consideration.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20136916     DOI: 10.1111/j.1529-8019.2009.01281.x

Source DB:  PubMed          Journal:  Dermatol Ther        ISSN: 1396-0296            Impact factor:   2.851


  20 in total

Review 1.  Obesity and its role in the management of rheumatoid and psoriatic arthritis.

Authors:  Luca Moroni; Nicola Farina; Lorenzo Dagna
Journal:  Clin Rheumatol       Date:  2020-02-03       Impact factor: 2.980

Review 2.  Effect of lifestyle weight loss intervention on disease severity in patients with psoriasis: a systematic review and meta-analysis.

Authors:  S Upala; A Sanguankeo
Journal:  Int J Obes (Lond)       Date:  2015-04-29       Impact factor: 5.095

3.  Psoriasis following bariatric surgery: clinical evolution and impact on quality of life on 10 patients.

Authors:  M M Farias; P Achurra; C Boza; A Vega; C de la Cruz
Journal:  Obes Surg       Date:  2012-06       Impact factor: 4.129

4.  Glucagon-like peptide-1 (GLP-1) receptor agonists, obesity and psoriasis: diabetes meets dermatology.

Authors:  D J Drucker; C F Rosen
Journal:  Diabetologia       Date:  2011-09-03       Impact factor: 10.122

5.  Factors associated with the length of remission of psoriasis vulgaris.

Authors:  Susana Coimbra; Hugo Oliveira; Américo Figueiredo; Petronila Rocha-Pereira; Alice Santos-Silva
Journal:  Clin Drug Investig       Date:  2013-11       Impact factor: 2.859

6.  Heterogeneity of response to biologic treatment: perspective for psoriasis.

Authors:  Emily Edson-Heredia; Kimberly L Sterling; Carlos I Alatorre; Gebra Cuyun Carter; Rosirene Paczkowski; Victoria Zarotsky; Tomoko Maeda-Chubachi
Journal:  J Invest Dermatol       Date:  2013-08-06       Impact factor: 8.551

Review 7.  Diet and psoriasis, part I: Impact of weight loss interventions.

Authors:  Maya Debbaneh; Jillian W Millsop; Bhavnit K Bhatia; John Koo; Wilson Liao
Journal:  J Am Acad Dermatol       Date:  2014-04-04       Impact factor: 11.527

8.  Influence of ustekinumab on body weight of patients with psoriasis: an initial report.

Authors:  Agnieszka Owczarczyk-Saczonek; Waldemar Placek; Joanna Rybak-d'Obyrn; Ewa Wygonowska
Journal:  Postepy Dermatol Alergol       Date:  2014-02-25       Impact factor: 1.837

Review 9.  Environmental Risk Factors in Psoriasis: The Point of View of the Nutritionist.

Authors:  Luigi Barrea; Francesca Nappi; Carolina Di Somma; Maria Cristina Savanelli; Andrea Falco; Anna Balato; Nicola Balato; Silvia Savastano
Journal:  Int J Environ Res Public Health       Date:  2016-07-22       Impact factor: 3.390

10.  The relationship between body mass index, waist circumference and psoriatic arthritis in the Turkish population.

Authors:  Dilek Biyik Ozkaya; Nahide Onsun; Bugce Topukçu; Ozlem Su; Anil Gulsel Bahalı; Didem Dizman; Aylin Rezvani; Omer Uysal
Journal:  Postepy Dermatol Alergol       Date:  2016-06-17       Impact factor: 1.837

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.